Compare INDI & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.1M | 1.0B |
| IPO Year | 2021 | 2007 |
| Metric | INDI | CDNA |
|---|---|---|
| Price | $3.42 | $18.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $6.25 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 3.2M | 643.7K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $217,394,000.00 | $48,324,000.00 |
| Revenue This Year | $32.19 | $12.18 |
| Revenue Next Year | $35.06 | $10.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.33 | ★ 18.93 |
| 52 Week Low | $1.53 | $10.96 |
| 52 Week High | $6.05 | $21.49 |
| Indicator | INDI | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 45.20 |
| Support Level | $3.18 | $18.30 |
| Resistance Level | $3.68 | $20.74 |
| Average True Range (ATR) | 0.26 | 1.00 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 13.02 | 44.56 |
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.